Eesti - eesti - Ravimiamet

leo pharma a/s - hüdrokortisoon+fusidiinhape - kreem - 10mg+20mg 1g 15g 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Eesti - eesti - Ravimiamet

accord healthcare b.v. - hüdroksüklorokviin - õhukese polümeerikattega tablett - 200mg 20tk; 200mg 60tk; 200mg 90tk; 200mg 100tk; 200mg 30tk; 200mg 50tk

Eesti - eesti - Ravimiamet

bioveta a.s. - pöögitõrv - nahasprei, lahus - 200mg 1g 80g 1tk

Eesti - eesti - Ravimiamet

kalceks as - deksametasoon - süste-/infusioonilahus - 4mg 1ml 2ml 5tk; 4mg 1ml 2ml 10tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - leukeemia, müeloid - antineoplastilised ained - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

janssen-cilag international n.v.   - detsitabiin - leukeemia, müeloid - antineoplastilised ained - Äsja diagnoositud de novo või sekundaarse ägeda müeloidse leukeemiaga (aml), maailma terviseorganisatsiooni (who) klassifikatsiooni järgi täiskasvanud patsientidele, kes ei ole kandidaadid standard induktsioonkemoteraapia.

Euroopa Liit - eesti - EMA (European Medicines Agency)

astellas pharma gmbh - takroliimus - dermatiit, atoopiline - muud dermatoloogilised preparaadid - mõõduka kuni raske atoopilise dermatiidiga täiskasvanutele, kes ei reageerinud piisavalt või ei talu tavapärast ravi, näiteks lokaalseid kortikosteroide. mõõduka kuni raske atoopilise dermatiidiga lastel (2-aastased ja vanemad), kes piisavalt ei allu konventsionaalsele ravile, näiteks lokaalseid kortikosteroide. hooldus-ravi mõõduka kuni raske atoopilise dermatiidi vältimiseks rakette ja pikendamise flare-vaba intervalliga patsientidel, kellel on suur sagedus haiguse ägenemised (ma. mis ilmneb 4 või rohkem korda aastas) kellel on osaline vastus kuni 6 nädalat ravi kaks korda ööpäevas takroliimuse salviga (kahjustusi kustutatud, peaaegu täielikult või nahakahjustus).

Eesti - eesti - Ravimiamet

b. braun melsungen ag - joodpovidoon - nahalahus - 75mg 1g 100ml 1tk; 75mg 1g 1000ml 1tk

Eesti - eesti - Ravimiamet

cnp pharma gmbh - vankomütsiin - infusioonilahuse pulber - 1000mg 5viaal; 1000mg 1viaal